Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2015-12-09 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a specific financial event: Genmab receiving a USD 5 million milestone payment from Janssen due to progress in a clinical study for daratumumab. It provides key highlights, context about the drug and study, and concludes with standard company information and forward-looking statements. This structure—a brief, focused announcement of a specific financial or operational event, rather than a comprehensive periodic report (like 10-K or IR) or a transcript—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full quarterly/annual report, nor a transcript, and it announces a specific financial achievement (milestone payment), it aligns best with the 'Earnings Release' category, which covers initial announcements of key financial/operational results. It is not a proxy statement (DEF 14A), a capital raise (CAP), or a dividend notice (DIV). Given the nature of the announcement (a specific financial milestone achievement), ER is the most appropriate fit among the provided options.
2015-12-09 English
Genmab når milestone på USD 5 mio. i daratumumab-samarbejdet med Janssen
Capital/Financing Update Classification · 75% confidence The document is a corporate press release announcing a USD 5 million milestone payment from Janssen following clinical progress. It does not contain financial statements or regulatory filings, nor is it an earnings release or dividend notice. Instead, it reports a financing-related transaction (milestone payment) under a collaboration agreement, which aligns with the Capital/Financing Update category (CAP).
2015-12-09 English
Genmab når milestone på USD 5 mio. i daratumumab-samarbejdet med Janssen
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab regarding a milestone payment of USD 5 million received from Janssen. It details the clinical progress of the drug daratumumab. Since this is a specific corporate announcement regarding business operations and financial milestones that does not fit into the categories of full financial reports, transcripts, or governance documents, it is classified as a Regulatory Filing (RNS).
2015-12-09 English
Regulatory Filings 2015
Regulatory Filings Classification · 98% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and is dated November 23, 2015. It announces a specific corporate event: the early termination of a Phase III clinical trial for the drug ofatumumab based on an interim analysis. This type of announcement, detailing a significant operational or clinical development that is material to investors but is not a full financial report (like 10-K or IR), typically falls under general regulatory announcements or investor relations communications. Since it is a specific, material update about clinical trial progress and results (or lack thereof), it is best classified as a general Regulatory Filing (RNS) as it is a mandatory disclosure to the market, or potentially an Investor Presentation (IP) if it were a presentation, but here it is a formal announcement. Given the context of mandatory disclosure of material non-public information in a press release format, RNS is the most appropriate general category for such specific, non-financial, operational news that doesn't fit the other specific codes (like DIV, CAP, MANG). The length (6571 chars) is substantial enough that it is the report itself, not just a notice of a report (RPA).
2015-11-23 Danish
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a specific operational event: the early stopping of a Phase III clinical study for a drug (ofatumumab) based on an interim analysis by an Independent Data Monitoring Committee (IDMC). This is a material event disclosure typical of a biotechnology or pharmaceutical company. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific operational update that doesn't fit the definitions for AGM-R, MANG, DIRS, LTR, or CAP. Since it is a specific, material announcement that doesn't fit the primary financial or governance categories, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant, non-standard announcements, or potentially a specialized regulatory filing not explicitly listed. Given the options, RNS is the most appropriate general regulatory announcement category for this type of clinical trial update.
2015-11-23 English
Earnings Release 2015
Earnings Release Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a specific corporate event: Genmab receiving a milestone payment from Janssen due to the first commercial sale of DARZALEX in the USA. This is a time-sensitive, material event announcement, not a comprehensive periodic report (like 10-K or IR), a transcript (CT), or a formal proxy/governance document. It is a specific operational/financial update. Since it is a formal announcement of a material event (milestone payment triggered by sales), it fits best under the general category for regulatory announcements that aren't covered by more specific codes like DIV, CAP, or ER. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-periodic, material company announcement that doesn't fit the other specific categories like Earnings Release (ER) or Capital Update (CAP). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to another document. FY 2015
2015-11-19 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.